Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Praveen Radhakrishnan

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
Scientific Reports|October 15, 2017
Pharmacological HIF-inhibition attenuates postoperative adhesion formationMoritz J Strowitzki, Alina S Ritter, Praveen Radhakrishnan, et al.
JCI Insight|December 12, 2022
The HIF-prolyl hydroxylases have distinct and nonredundant roles in colitis-associated cancerKilian B Kennel, Julius Burmeister, Praveen Radhakrishnan, et al.
Oncotarget|October 8, 2016
LDB1 overexpression is a negative prognostic factor in colorectal cancerSebastián A García, Anka Swiersy, Praveen Radhakrishnan, et al.
Annals of Surgery|March 8, 2017
Prolyl Hydroxylase Inhibition Enhances Liver Regeneration Without Induction of Tumor GrowthJonathan M Harnoss, Lisa K Platzer, Juergen Burhenne, et al.
Inflammatory Bowel Diseases|October 17, 2019
Prolyl Hydroxylase Inhibition Mitigates PouchitisJonathan M Harnoss, Jasper M Gebhardt, Praveen Radhakrishnan, et al.
American Journal of Physiology. Gastrointestinal and Liver Physiology|October 30, 2016
Hydroxylase inhibition regulates inflammation-induced intestinal fibrosis through the suppression of ERK-mediated TGF-β1 signaling. [corrected]Mario C Manresa, Murtaza M Tambuwala, Praveen Radhakrishnan, et al.
JCI Insight|March 30, 2021
Inhibition of HIF-prolyl hydroxylases improves healing of intestinal anastomosesMoritz J Strowitzki, Gwendolyn Kimmer, Julian Wehrmann, et al.
Cancer Cell|June 10, 2020
Reduction of Liver Metastasis Stiffness Improves Response to Bevacizumab in Metastatic Colorectal CancerYing Shen, Xiaohong Wang, Junyan Lu, et al.
EMBO Molecular Medicine|August 21, 2015
PHD1 regulates p53-mediated colorectal cancer chemoresistanceSofie Deschoemaeker, Giusy Di Conza, Sergio Lilla, et al.
Cell Death & Disease|August 19, 2016
Bcl-xL is an oncogenic driver in colorectal cancerAnna-Lena Scherr, Georg Gdynia, Mariam Salou, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Scientific Reports|October 15, 2017
Pharmacological HIF-inhibition attenuates postoperative adhesion formationMoritz J Strowitzki, Alina S Ritter, Praveen Radhakrishnan, et al.
JCI Insight|December 12, 2022
The HIF-prolyl hydroxylases have distinct and nonredundant roles in colitis-associated cancerKilian B Kennel, Julius Burmeister, Praveen Radhakrishnan, et al.
Oncotarget|October 8, 2016
LDB1 overexpression is a negative prognostic factor in colorectal cancerSebastián A García, Anka Swiersy, Praveen Radhakrishnan, et al.
Annals of Surgery|March 8, 2017
Prolyl Hydroxylase Inhibition Enhances Liver Regeneration Without Induction of Tumor GrowthJonathan M Harnoss, Lisa K Platzer, Juergen Burhenne, et al.
Inflammatory Bowel Diseases|October 17, 2019
Prolyl Hydroxylase Inhibition Mitigates PouchitisJonathan M Harnoss, Jasper M Gebhardt, Praveen Radhakrishnan, et al.
American Journal of Physiology. Gastrointestinal and Liver Physiology|October 30, 2016
Hydroxylase inhibition regulates inflammation-induced intestinal fibrosis through the suppression of ERK-mediated TGF-β1 signaling. [corrected]Mario C Manresa, Murtaza M Tambuwala, Praveen Radhakrishnan, et al.
JCI Insight|March 30, 2021
Inhibition of HIF-prolyl hydroxylases improves healing of intestinal anastomosesMoritz J Strowitzki, Gwendolyn Kimmer, Julian Wehrmann, et al.
Cancer Cell|June 10, 2020
Reduction of Liver Metastasis Stiffness Improves Response to Bevacizumab in Metastatic Colorectal CancerYing Shen, Xiaohong Wang, Junyan Lu, et al.
EMBO Molecular Medicine|August 21, 2015
PHD1 regulates p53-mediated colorectal cancer chemoresistanceSofie Deschoemaeker, Giusy Di Conza, Sergio Lilla, et al.
Cell Death & Disease|August 19, 2016
Bcl-xL is an oncogenic driver in colorectal cancerAnna-Lena Scherr, Georg Gdynia, Mariam Salou, et al.
Pageof 4